AbbVie: Risankizumab Meets Primary Endpoints In Fourth Phase 3 Psoriasis Study

AbbVie (ABBV) announced positive top-line results from IMMhance, the fourth pivotal Phase 3 clinical trial evaluating risankizumab (150 mg) for the treatment of patients with moderate to severe plaque psoriasis.

from RTT - Biotech http://ift.tt/2AoWIA7
via IFTTT